Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.63 USD | -2.23% | +3.54% | -19.45% |
24/04 | Gain Therapeutics, Inc. Announces Positive Results from the Single Ascending Dose Part of the Phase 1 Clinical Trial of GT-02287 | CI |
08/04 | Gain Therapeutics Names Gene Mack as CFO | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.45% | 4.86Cr | |
+33.63% | 5.08TCr | |
-0.09% | 4.28TCr | |
+49.62% | 4.2TCr | |
-4.96% | 2.95TCr | |
+11.18% | 2.61TCr | |
-21.95% | 1.91TCr | |
+8.61% | 1.31TCr | |
+28.31% | 1.22TCr | |
+24.73% | 1.21TCr |
- Stock Market
- Equities
- GANX Stock
- News Gain Therapeutics, Inc.
- HC Wainwright Initiates Gain Therapeutics at Buy With $12 Price Target